BEAT

Rating neutralTentativeAI Memo

HeartBeam

As of 2026-09-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

ALIGN-ACS results at TCT 2026 • 2026-10-31

Base target: $0 / p=45% prob

Biggest risk

Heart-attack assessment remains unapproved, the pivotal study is not yet established, and limited commercialization reduces near-term revenue evidence. Disappointing data, a burdensome FDA pathway or continuing cash burn could force dilutive financing.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Positive ALIGN-ACS data, a workable pivotal-study pathway and a funded partner for the patch could validate the sharper clinical focus. The September strategy may conserve capital by avoiding a large arrhythmia sales build-out [#IR-2026-09-21] (shareholder letter).

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-25

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Cash-burn reduction versus financing risk
Patch partnering and focused commercialization
Positive ALIGN-ACS data, a workable pivotal-study pathway and a funded partner for the patch could validate the sharper clinical focus.

BearKey bullets

ALIGN-ACS is a pilot; clinical performance, pivotal-study requirements and the timing of any expanded indication remain uncertain.
Current FDA clearance is for arrhythmia assessment, not myocardial infarction or ischemia [#IR-2026-09-21] (company indications in shareholder letter).
June 30 cash and ongoing operating use create dilution risk despite management's projected runway into 2027 [#IR-2026-08-13] (company results).

WatchKey bullets

ALIGN-ACS results at TCT 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $0 (p=45%)

Target spread vs base: +70% / -60%

Scenario probabilities

Bull Target: $1 (p=25%)Base Target: $0 (p=45%)Bear Target: $0 (p=30%)

Commentary

Company updates are constructive on pilot enrollment and cost reductions, but the September 21 letter materially narrows the near-term commercialization thesis. Reliable analyst revisions, post-release price-reaction attribution, options skew, short interest and sufficient social coverage were not available; zero sentiment fields above denote unavailable data, not measured neutral readings. Coverage is thin, and the supplied positive deterministic score does not resolve clinical or financing uncertainty.

As of 2026-09-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Cash-burn reduction versus financing risk
Patch partnering and focused commercialization

Scenarios

Bull Target (Scenario probability)

$1 / p=25% prob

Base Target (Scenario probability)

$0 / p=45% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Analysis 2026-09-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-31
ALIGN-ACS results at TCT 2026
HeartBeam says full results from its 134-patient heart-attack detection pilot will be presented at TCT, October 31–November 3. The data may clarify the case for a U.S. pivotal study but will not constitute FDA approval [#IR-2026-08-13] (company release).
Prob 75.00% • Move 30.00% • Priced-in 30.00%
EVENT2026-12-31
FDA feedback and pivotal-study design
HeartBeam said it submitted a pre-submission request in August and expects further timeline detail by year-end. Trial requirements or delays could materially change funding needs; its current clearance does not cover heart-attack assessment [#IR-2026-09-21] (shareholder letter).
Prob 55.00% • Move 25.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

Cash-burn reduction versus financing risk
2026-12-31
The Q2 reporting period is documented in the August 10-Q [#10-Q-2026-08-13]. HeartBeam reported $8.7 million of cash and equivalents at June 30 and $3.3 million of Q2 operating cash use; it projected a Q4 baseline below $2.5 million. Demonstrating that reduction matters because further equity funding could dilute holders [#IR-2026-08-13] (company results).
Prob 55% • Move 15% • Priced-in 25%

Long-term Catalysts

Months to a year

Patch partnering and focused commercialization
2027-06-30
The September shareholder letter redirected most resources toward heart-attack detection, kept existing arrhythmia-product commercialization limited, and proposed a strategic partner for the 12-lead patch. A signed, economically meaningful agreement—not discussions alone—would strengthen the case [#IR-2026-09-21] (shareholder letter).
Prob 35% • Move 25% • Priced-in 15%

Risks

ALIGN-ACS is a pilot; clinical performance, pivotal-study requirements and the timing of any expanded indication remain uncertain.
Current FDA clearance is for arrhythmia assessment, not myocardial infarction or ischemia [#IR-2026-09-21] (company indications in shareholder letter).
June 30 cash and ongoing operating use create dilution risk despite management's projected runway into 2027 [#IR-2026-08-13] (company results).
The September decision not to build a large arrhythmia commercial organization limits near-term sales validation; patch-partner discussions are not a signed transaction [#IR-2026-09-21] (shareholder letter).

Peers

Symbol	Summary
ABT	Established cardiac-device adoption benchmark, not a direct valuation comparable to a pre-scale micro-cap.
BSX	Provides cardiovascular-device commercialization context, but scale, diversification and profitability make a direct multiple comparison inappropriate.
HSCS	Closest candidate by small size and cardiac-diagnostics focus, but its products and development path differ; use only as a speculative-device risk reference.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-25

Loading AI feed…

Symbol

Summary

ABT

Established cardiac-device adoption benchmark, not a direct valuation comparable to a pre-scale micro-cap.

BSX

Provides cardiovascular-device commercialization context, but scale, diversification and profitability make a direct multiple comparison inappropriate.

HSCS

Closest candidate by small size and cardiac-diagnostics focus, but its products and development path differ; use only as a speculative-device risk reference.